LEMBOREXANT TAB
Clinical Criteria Summary
Exclusion Criteria
- Narcolepsy
- Co-administration with strong or moderate CYP3A4 inhibitors and inducers
- Active substance use disorder
- Actively suicidal or evaluated as being a high suicide risk
- Untreated significant sleep-related breathing disorder-obstructive or central sleep apnea syndrome
- Severe hepatic impairment (e.g., Child-Pugh C)
- History of complex sleep behaviors
Inclusion Criteria
- Prescribed and monitored by a VA / VA Community Care sleep specialist or locally designated expert in sleep disorders
- Documented diagnosis of insomnia characterized by difficulties with sleep onset and/or sleep maintenance
- When available, cognitive behavioral therapy for Insomnia (CBT-I) has been tried, via face to face, tele-mental health or non-VA care
- An adequate short-term trial of 2 formulary sedative hypnotics for the treatment of sleep onset and maintenance have been tried and failed to resolve symptoms or were not tolerated
- An adequate trial of daridorexant has been tried and failed or was not tolerated